NDAORALTABLET
Approved
Aug 2007
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
FENOGLIDE (fenofibrate) by Salix Pharmaceuticals is α (pparα). First approved in 2007.
Drug data last refreshed 7h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FENOGLIDE (fenofibrate) is an oral small-molecule fibrate approved in 2007 that activates peroxisome proliferator-activated receptor alpha (PPARα) to reduce triglycerides and improve lipid profiles. It works by increasing lipolysis, reducing apoprotein C-III production, and shifting LDL particle composition toward larger, less atherogenic forms while raising HDL cholesterol. The drug is indicated for patients with elevated triglycerides and dyslipidemia.
LOE Approaching
As LOE approaches, the brand team is likely consolidating and shifting focus toward lifecycle management, patient retention, and managed care negotiations rather than growth-stage expansion.
Mechanism of Action
α (PPARα). Through this mechanism, fenofibrate increases lipolysis and elimination of triglyceride-rich particles from plasma by activating lipoprotein lipase and reducing production of apoprotein C-III (an inhibitor of lipoprotein lipase activity). The resulting fall in triglycerides produces an…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Choline Fenofibrate and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined Dyslipidemia
Started Jun 2023
56 enrolled
DyslipidemiaAtherosclerosisDiabetes Mellitus, Type 2
Fenofibrate for Prevention of DR Worsening
Started Mar 2021
560 enrolled
Diabetic Retinopathy
Fenofibrate for Patients With COVID-19 Requiring Hospitalization
Started Jan 2021
55 enrolled
Corona Virus Disease (COVID-19)Respiratory Distress SyndromeSARS-CoV-2 Infection
Cinical Trial to Explore the Efficacy of Statin/Choline Fenofibrate Combination Therapy vs Statin Monotherapy in Patients With Inadequately Controlled TG Despite Receiving Statin Monotherapy
Started Jul 2018
180 enrolled
Dyslipidemias
Study to Evaluate the Pharmacokinetics of Firsocostat or Fenofibrate in Adults With Normal and Impaired Hepatic Function
Started Sep 2016
74 enrolled
Nonalcoholic Steatohepatitis (NASH)
Worked on FENOGLIDE at Salix Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.